Abstract. Regional and distant metastases are the principal reasons underlying the high mortality rate associated with tongue squamous cell carcinoma (TSCC); however, the precise molecular mechanisms involved in tongue tumorigenesis remain unknown. The present study aimed to determine the expression and mechanism of regulation of Wnt7a in the growth and metastasis of TSCC. Wnt7a mRNA and protein expression levels were examined in TSCC tissues using reverse transcription-quantitative polymerase chain reaction and immunohistochemical staining. A loss-of-function assay was performed in TSCC cell lines using Wnt7a small interfering RNA or short hairpin RNA, after which, cell proliferation, migration and invasion were analyzed using Cell Counting Kit-8, tumorigenicity and Transwell assays, respectively. Epithelial-mesenchymal transition (EMT)-associated proteins were detected by western blotting. The mRNA and protein expression levels of Wnt7a were significantly upregulated in cancer tissues compared with in the adjacent non-cancerous tissues. Clinical analysis indicated that Wnt7a expression was associated with T classification, lymph node metastasis and pathological differentiation, and high Wnt7a expression predicted a short recurrence-free survival for patients with TSCC. Silencing Wnt7a expression suppressed cell proliferation, migration and invasion, and reversed the EMT phenotype in TSCC cell lines. The present study revealed that Wnt7a may be upregulated in TSCC, where it may participate in modulating cell proliferation, migration, invasion and the EMT of TSCC. Therefore, Wnt7a should be considered a novel oncogene, and a potential prognostic and therapeutic target for patients with TSCC.

Introduction

Tongue squamous cell carcinoma (TSCC) is one of the most common types of head and neck cancer (HNC) (1,2); >3,000 people worldwide are diagnosed with TSCC annually and it accounts for 24% of all HNC cases (3). Although many patients are identified at the earlier stages of the disease, the 5-year survival rate for advanced-stage TSCC is only ~50%, due to high invasiveness and metastasis (4). In addition, no effective drugs are currently available for the treatment and control of regional and distant metastases of TSCC. Therefore, screening novel methods for the diagnosis, prognosis and treatment of TSCC may result in a significant clinical advancement.

TSCC is caused by the interaction of numerous genes, the increased expression of proto-oncogenes and inhibition of tumor suppressor genes. Furthermore, cell signaling pathways, such as p53 (5), Ras (6), mitogen-activated protein kinase, Janus kinase/signal transducer and activator of transcription (7), Wnt and hedgehog (8) signaling pathways serve important roles in the development of TSCC. The Wnt protein family is a group of 19 secreted glycoproteins (9); Wnt proteins transmit signals to cells through ≥15 receptors or collaborative receptors, thus resulting in regulation of the differentiation, apoptosis and proliferation of epithelial cells (10,11). Postoperative metastasis leads to unfavorable outcomes in patients with TSCC, and epithelial-mesenchymal transition (EMT) is considered the fundamental event of cancer metastasis and recurrence (12,13). It is well known that EMT is regulated by a series of molecular factors, including Wnt signaling-related genes (14). Wnt7a is a member of the Wnt family, which has not yet been studied in TSCC. β-catenin is a core transducer in the canonical Wnt signaling pathway and is an EMT-associated marker (15). Previous studies have indicated the important role of β-catenin in EMT, thus bridging a crosstalk between the Wnt pathway and EMT (16,17). In addition, the positive correlation between Wnt7a and the Wnt/β-catenin pathway has been discussed previously (18); therefore, it is of great value to explore the role of Wnt7a in the EMT process during TSCC progression. The present study focused on Wnt7a and the Wnt pathway; however, research regarding the interaction...
between Wnt7a and other pathways may be conducted in the future.

Wnt7a has been reported to be highly associated with the progression of cell growth through regulating transforming growth factor (TGF)-β receptor and activating the cancer-associated fibroblast phenotype (19). Wnt7a has been reported to be overexpressed in colorectal, pancreatic, gastric, breast and ovarian carcinoma (20). Conversely, in non-small-cell lung carcinoma, Wnt7a may function as a tumor suppressor gene (21). In addition, the Wnt7a gene has been reported to be downregulated by high-frequency hypermethylation in pancreatic carcinoma (22). The overexpression of Wnt7a has been demonstrated to enhance the invasiveness and metastasis of ovarian cancer cells, possibly through the Frizzled receptor (23). These results suggested that Wnt7a may regulate the proliferation and adhesion of cancer cells; however, its role in tumor cell proliferation and migration may be dependent on tumor type. However, the clinical significance of Wnt7a expression in TSCC has not yet been revealed. Therefore, it is of great significance to determine the expression levels of Wnt7a in TSCC tissues, and to assess its clinical implications. Furthermore, the mechanism underlying the regulatory effects of Wnt7a on cell proliferation, metastasis and EMT in TSCC was investigated.

Materials and methods

Tissue samples. Two independent cohorts, comprising 109 patients with TSCC who were diagnosed, treated and followed up at the Stomatological Hospital, Southern Medical University (Guangzhou, China) between November 2010 and May 2014, were recruited to the present study. All patients provided informed consent for the use of their tissues and clinical data. Specimens, including paired cancerous and non-cancerous tissues, were obtained following surgical resection. Samples were immediately frozen using liquid nitrogen after resection and were stored at -80˚C prior to RNA extraction (cohort 1, n=48), or were fixed in 4% paraformaldehyde at room temperature for 24-48 h and embedded in paraffin for immunohistochemistry (IHC; cohort 2, n=61). All patients were initially diagnosed with tongue cancer and did not receive any other treatment prior to surgery. The present study was approved by the Independent Ethics Committee of the Stomatological Hospital, Southern Medical University (approval no. [2018]05).

Cell culture. The CAL-27, SCC-15 and SCC-9 human TSCC cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). HSC-4 was purchased from the Human Science Research Resources Bank of the Japan Health Sciences Foundation (Tokyo, Japan). Human oral keratinocytes were purchased from ScienCell Research Laboratories, Inc. (San Diego, CA, USA). CAL-27 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), HSC-4 cells were cultured in Eagle's Minimum Essential Medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.), and SCC-15 and SCC-9 cells were maintained in a 1:1 mixture of DMEM and Ham's F12 medium (Gibco; Thermo Fisher Scientific, Inc.). For complete growth medium, fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) was added to the media at a final concentration of 10%. The cells were maintained at 37˚C in a humidified atmosphere containing 5% CO2.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from tissues and cell lines using RNAiso Plus reagent (Takara Bio, Inc., Otsu, Japan), followed by RT using PrimeScript First-Strand cDNA Synthesis kit (Takara Bio, Inc.), according to the manufacturer's protocols. The mRNA expression levels of Wnt7a were evaluated by qPCR using a SYBR® Premix Ex Taq™ kit (cat. no. RR420A; Takara Bio, Inc.) on the StepOnePlus Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The RT-qPCR primers used were as follows: Wnt7a, forward 5'-CCAGACA AAAACCTTGAGCCC-3'; reverse 5'-CCTTTGTCAGGT AGCGAGCA-3'; and β-actin, forward 5'-CGTCACCACACTG GGACGACA-3' and reverse 5'-CTTCTCGGGTTGCCCT GG-3'. β-actin was employed as an endogenous control. Target and endogenous control genes were amplified in triplicate and the relative mRNA expression levels of Wnt7a for each sample were calculated using the 2-ΔΔCq method (24).

IHC. Paraffin-embedded sections (4 µm) were cut and mounted onto slides, after which, paraffin was removed with xylene and the sections were rehydrated in an alcohol gradient. Subsequently, the sections were treated with citrate buffer for antigen retrieval in a microwave oven for 10 min at 95˚C and were then cooled to room temperature. The sections were then immersed in 3% H2O2 for 15-20 min at room temperature, blocked with 5% bovine serum albumin (EMD Millipore, Billerica, MA, USA) for 30 min at room temperature, and incubated with the Wnt7a primary antibody (cat. no. 10605-1-AP; 1:200; ProteinTech Group, Inc., Chicago, IL, USA) at 4˚C overnight. The next day, sections were incubated with HRP-conjugated goat anti-rabbit IgG (cat. no. TA130023; OriGene Technologies, Inc., Beijing, China) for 15 min at room temperature to detect primary antibody. Finally, the slides were incubated with DAB (cat. no. PV-6000; ZSGB-BIO; OriGene Technologies, Inc.) and were observed under an upright light microscope.

Two individual pathologists evaluated positive staining of Wnt7a in TSCC tissues. Cytoplasmic brown staining in tumor cells was considered positive and was scored based on the following criteria: i) Staining intensity: 0, negative Wnt7a staining; 1, weak staining; 2, moderate staining; and 3, strong staining. ii) Percentage of stained tumor cells was categorized into four classes, 0, negative; 1, ≤25%; 2, 26-50%; 3, 51-74%; and 4, ≥76%. Finally, Wnt7a protein expression was scored semi-quantitatively by multiplying the aforementioned scores.

Gene silencing. When cells reached a confluence of ~70%, small interfering (si)RNAs (Sangon Biotech Co., Ltd., Shanghai, China) targeting Wnt7a mRNA (siWnt7a-1: 5'-AAAUUGUA AAUAUUGUCUGU-3'; siWnt7a-2: 5'-UUAUUAAUUAUU UAUAGAAA-3') were transfected at a concentration of 50 nmol/l to induce transient knockdown of Wnt7a expression using Lipofectamine® 3000 transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The cells were collected for subsequent experiments.

Gene silencing. When cells reached a confluence of ~70%, small interfering (si)RNAs (Sangon Biotech Co., Ltd., Shanghai, China) targeting Wnt7a mRNA (siWnt7a-1: 5'-AAAUUGUA AAUAUUGUCUGU-3'; siWnt7a-2: 5'-UUAUUAAUUAUU UAUAGAAA-3') were transfected at a concentration of 50 nmol/l to induce transient knockdown of Wnt7a expression using Lipofectamine® 3000 transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The cells were collected for subsequent experiments.
after 48-72 h incubation. The negative control (NC) sequence was as follows: 5'‑UUCCUGGAACGUCAGCUTT‑3'.

For the construction of stable Wnt7a-knockdown cell models, CAL‑27 cells underwent lentivirus‑mediated infection with short hairpin (sh)RNA (Sangon Biotech Co., Ltd.) targeting Wnt7a mRNA (5'-AAA UUG UUA AAU AUU GCUG‑G‑3') or the NC sequence (5'-UUCCUGGAACGUCAGCUTT‑3') at a multiplicity of infection (MOI) of 20, according to the manufacturer's protocol. After 8 h culture, the lentivirus-containing culture medium was replaced with fresh medium. The efficiency of lentivirus-mediated RNA interference was determined by RT‑qPCR and western blotting.

**Cell proliferation assay.** Cell proliferation was measured using the Cell Counting Kit‑8 (CCK‑8) (Dojindo Molecular Laboratories, Inc., Kumamoto, Japan). CAL‑27 and SCC‑15 cells were collected, resuspended and seeded onto 96‑well plates, at a density of 3x10³ cells/well. After adherence, cells were transfected with Wnt7a siRNA or NC siRNA. After a further incubation for 0, 24, 48, 72 and 96 h, 10 µl CCK‑8 reagent was added to each well, and absorbance was measured at 450 nm using a microplate reader (SpectraMax Plus 384; Molecular Devices, LLC, Sunnyvale, CA, USA) after 2 h incubation at 37°C.

**Tumorigenicity assay.** BALB/c male nude mice (specific pathogen‑free grade; weight, 14‑16 g; age, 3‑4 weeks) were purchased from the Laboratory Animal Center of Southern Medical University. Lentiviral‑mediated stable Wnt7a‑knockdown CAL‑27 cells and NC cells were subcutaneously injected into the flanks of nude mice (n=5 in each group). Subsequently, the mice were maintained in a specific pathogen‑free grade lab, under the following conditions: Controlled temperature, 23±2°C; humidity, 40‑70%; 12‑h light/dark cycle) at the Laboratory Animal Center of Nanfang Hospital, Southern Medical University (Guangzhou, China) with ad libitum access to food and water for 4 weeks. The volume of xenograft tumors was monitored every 3 days by measuring the length and width (Volume = length x width x π/6). The animal study was conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines, and was approved by Experimental Animal Ethics Committee of Southern Medical University (approval no. L2016113).

**Transwell migration and invasion assays.** For the migration assay, a total of 5x10³ CAL‑27 or SCC‑15 cells transfected with Wnt7a siRNA or NC siRNA were collected and resuspended in 200 µl serum‑free medium. The cells were added to the upper chamber of a Transwell insert (Corning Incorporated, Corning, NY, USA) placed in a 24‑well plate, whereas 500 µl complete medium containing 10% FBS was added to the lower chamber. After 24 h culture, cells on the upper surface of the filter were removed and cells on the lower surface were stained with 0.1% crystal violet for 20 min at room temperature. Cells that migrated through the filters were counted and images were captured in five random fields at a magnification of x400 using an inverted light microscope. For the invasion assay, the chambers were pre-coated with Matrigel matrix (Corning Incorporated) diluted with serum‑free medium in a ratio of 1:8.

Western blotting. Cells were lysed in radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) supplemented with 1% protease inhibitors and phenylmethylsulfonyl fluoride. Subsequently, after determining the concentration of samples using a bicinchoninic acid protein assay kit (cat. no. K3000; Shanghai Bocai Biotechnology Co., Ltd., Shanghai, China), 30 µg protein was separated by 10% SDS‑PAGE and transferred onto polyvinylidene difluoride membranes (EMD Millipore). After blocking non‑specific antigens with 5% skimmed milk for 1 h at room temperature, membranes were incubated with primary antibodies at 4°C overnight. Subsequently, the membranes were washed and incubated with HRP-conjugated goat anti‑rabbit secondary antibody (cat. no. D110058; 1:10,000; BBI Life Sciences, Shanghai, China) for 1 h at room temperature. Finally, signals were visualized using the enhanced chemiluminescence detection system (Hangzhou Fude Biological Technology Co., Ltd., Hangzhou, China).

**Statistical analysis.** Statistical analysis was conducted using IBM SPSS Statistics 20.0 (IBM Corporation, Armonk, NY, USA). Data from triplicate experiments are presented as the means ± standard error of the mean. The associations between Wnt7a mRNA/protein expression and clinicopathological parameters were assessed using the χ² test. Student's t‑test was used to analyze the differences between two groups. One‑way analysis of variance followed by least significant difference test, or Kruskal‑Wallis test, was used to compare multiple groups. Survival data were evaluated using the Kaplan‑Meier method and log‑rank test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Upregulation of Wnt7a in human TSCC tissues.** Wnt7a expression was detected in the two cohorts of patients with TSCC, which comprised 109 pairs of TSCC specimens and adjacent non-cancerous tissues, using RT‑qPCR and IHC. The present study aimed to determine the role of Wnt7a in TSCC. In cohort 1, upregulation of Wnt7a mRNA was observed in TSCC tissues in 72.9% (35/48) of patients (Fig. 1A). The mRNA expression levels of Wnt7a were significantly increased in TSCC tissues compared with the corresponding adjacent normal tissues (Fig. 1B). Furthermore, IHC staining revealed that Wnt7a protein, which is primarily located in the cytoplasm, was significantly overexpressed in TSCC tissues compared...
with in matching adjacent normal tissues (Fig. 1C and D). These results suggested that Wnt7a was upregulated in TSCC tissues and may exert a role in carcinogenesis and its progression.

**Association between Wnt7a expression and clinicopathological parameters in patients with TSCC.** The association between Wnt7a expression and clinicopathological parameters was analyzed to assess the effects of Wnt7a on TSCC. In cohort 1, the patients were categorized into low or high expression groups according to the median value. Wnt7a mRNA expression was strongly associated with T classification ($P=0.039$), lymph node metastasis ($P=0.020$), pathological differentiation ($P=0.037$) and clinical stage ($P=0.020$; Table I). In cohort 2, TSCC tissues with a staining index of $>4$ were defined as the high expression group, whereas those with a staining index $\leq 4$ were defined as the low expression group. Results demonstrated that Wnt7a protein expression was positively associated with T classification ($P=0.033$), lymph node metastasis ($P=0.001$), pathological differentiation ($P<0.0001$), and clinical stage ($P=0.002$; Table II). Further analyses revealed that Wnt7a protein expression was
Table I. Association between Wnt7a mRNA expression and clinicopathological parameters in patients with tongue squamous cell carcinoma (n=48).

<table>
<thead>
<tr>
<th>Clinicopathological parameters</th>
<th>Low (n=24)(%)</th>
<th>High (n=24)(%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td>0.365</td>
</tr>
<tr>
<td>Male</td>
<td>14 (45.2)</td>
<td>17 (54.8)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>10 (58.8)</td>
<td>7 (41.2)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td>0.755</td>
</tr>
<tr>
<td>&lt;60</td>
<td>17 (51.5)</td>
<td>16 (48.5)</td>
<td></td>
</tr>
<tr>
<td>≥60</td>
<td>7 (46.7)</td>
<td>8 (53.3)</td>
<td></td>
</tr>
<tr>
<td>T classification</td>
<td></td>
<td></td>
<td>0.039</td>
</tr>
<tr>
<td>T1/T2</td>
<td>17 (65.4)</td>
<td>9 (34.6)</td>
<td></td>
</tr>
<tr>
<td>T3/T4</td>
<td>7 (31.8)</td>
<td>15 (68.2)</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td>0.020</td>
</tr>
<tr>
<td>Positive</td>
<td>7 (30.4)</td>
<td>16 (69.6)</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>17 (68.0)</td>
<td>8 (32.0)</td>
<td></td>
</tr>
<tr>
<td>Pathological differentiation</td>
<td></td>
<td></td>
<td>0.037</td>
</tr>
<tr>
<td>Well</td>
<td>11 (78.6)</td>
<td>3 (21.4)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>7 (41.2)</td>
<td>10 (58.8)</td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>6 (35.3)</td>
<td>11 (64.7)</td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td>0.020</td>
</tr>
<tr>
<td>I+II</td>
<td>15 (68.2)</td>
<td>7 (31.8)</td>
<td></td>
</tr>
<tr>
<td>III+IV</td>
<td>9 (34.6)</td>
<td>17 (65.4)</td>
<td></td>
</tr>
</tbody>
</table>

Data were analysed using χ² test.

Table II. Association between Wnt7a protein expression and clinicopathological parameters in patients with TSCC (n=61).

<table>
<thead>
<tr>
<th>Clinicopathological parameters</th>
<th>Low (n=27)(%)</th>
<th>High (n=34)(%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td>0.288</td>
</tr>
<tr>
<td>Male</td>
<td>13 (38.2)</td>
<td>21 (61.8)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>14 (51.9)</td>
<td>13 (48.1)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td>0.134</td>
</tr>
<tr>
<td>&lt;60</td>
<td>24 (49.0)</td>
<td>25 (51.0)</td>
<td></td>
</tr>
<tr>
<td>≥60</td>
<td>3 (25.0)</td>
<td>9 (75.0)</td>
<td></td>
</tr>
<tr>
<td>T classification</td>
<td></td>
<td></td>
<td>0.033</td>
</tr>
<tr>
<td>T1/T2</td>
<td>20 (55.6)</td>
<td>16 (44.4)</td>
<td></td>
</tr>
<tr>
<td>T3/T4</td>
<td>7 (28.0)</td>
<td>18 (72.0)</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td>0.001</td>
</tr>
<tr>
<td>Positive</td>
<td>8 (24.2)</td>
<td>25 (75.8)</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>19 (67.9)</td>
<td>9 (32.1)</td>
<td></td>
</tr>
<tr>
<td>Pathological differentiation</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Well</td>
<td>15 (88.2)</td>
<td>2 (11.8)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>8 (28.6)</td>
<td>20 (71.4)</td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>4 (25.0)</td>
<td>12 (75.0)</td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td>0.002</td>
</tr>
<tr>
<td>I+II</td>
<td>16 (69.6)</td>
<td>7 (30.4)</td>
<td></td>
</tr>
<tr>
<td>III+IV</td>
<td>11 (28.9)</td>
<td>27 (71.1)</td>
<td></td>
</tr>
</tbody>
</table>

Data were analysed using χ² test.
higher in tissues obtained from patients with lymph node metastasis (Fig. 1E), poor differentiation (Fig. 1F) and advanced TSCC (Fig. 1G). Wnt7a mRNA expression was also higher in tissues obtained from patients with lymph node metastasis (Fig. 1E) and advanced TSCC (Fig. 1G); however, it was not significantly associated with differentiation (P=0.087; Fig. 1F).

Furthermore, patients with higher Wnt7a mRNA (median recurrence-free survival, 1,366 days vs. 681 days, P=0.039) and protein (median recurrence-free survival, 1,305 days vs. 469 days, P=0.024) expression had a shorter recurrence-free survival (Fig. 1H).

Construction of Wnt7a-knockdown TSCC cell models. Since high Wnt7a expression was associated with malignant phenotypes in patients with TSCC, the present study aimed to investigate the effects of Wnt7a on TSCC carcinogenesis and progression. BioGPS (http://biogps.org/#goto=welcome) was used to observe Wnt7a mRNA expression in TSCC cell lines. A total of 10/17 TSCC cell lines recorded in the BioGPS exhibited elevated Wnt7a mRNA expression levels (Fig. 2A). The present study validated its expression in five cell lines using RT-qPCR; the results revealed that CAL-27 and SCC-15 cells exhibited the highest Wnt7a mRNA expression levels (Fig. 2B). To construct Wnt7a-knockdown TSCC cell models, two specific siRNAs targeting Wnt7a were transfected into CAL-27 and SCC-15 cell lines. Wnt7a siRNA transfection effectively knocked down the mRNA and protein expression of Wnt7a in CAL-27 and SCC-15 cells, as verified by RT-qPCR and western blotting, respectively (Fig. 2C and D).

Knockdown of Wnt7a suppresses proliferation of TSCC cells in vitro and in vivo. To detect the effects of Wnt7a on cell proliferation in TSCC cell lines, a CCK-8 assay was performed. In addition, a tumorigenicity assay was performed in nude mice following implantation of Wnt7a-knockdown cells. As shown in Fig. 3A, cells transfected with siRNAs against Wnt7a exhibited reduced growth compared with in the NC group, thus indicating that the knockdown of Wnt7a may significantly suppress the proliferative ability in CAL-27 and SCC-15 cells. In addition, xenograft models were successfully constructed in BALB/c nude mice, using stable Wnt7a-knockdown CAL-27 cells (Fig. 3B). The results revealed that tumor volumes in the shRNA-Wnt7a group were markedly smaller than in the NC group (Fig. 3C). The tumor growth curves also revealed that knockdown of Wnt7a substantially inhibited tumor growth (Fig. 3D). These results indicated that Wnt7a knockdown suppressed the proliferation of TSCC cells.

Knockdown of Wnt7a suppresses migration and invasion of TSCC cells in vitro. Since Wnt7a expression was positively

Figure 2. Expression of Wnt7a mRNA in TSCC cell lines and construction of Wnt7a-knockdown TSCC cell models. (A) Wnt7a mRNA expression in 17 TSCC cell lines from bioGPS. (B) Wnt7a mRNA expression in four TSCC cell lines, normalized to HOK, as detected by RT-qPCR. Wnt7a was efficiently downregulated following transfection of CAL-27 and SCC-15 cells with siRNA, as validated by (C) RT-qPCR (one-way analysis of variance and least significant difference test) and (D) western blotting. *P<0.05, **P<0.01. HOK, human oral keratinocytes; NC, negative control; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; Si/siRNA, small interfering RNA.
associated with lymph node metastasis, the present study further assessed the effects of Wnt7a on migration and invasion. Following Wnt7a knockdown, the numbers of cells that migrated (P<0.001; Fig. 4A) and invaded (P<0.001; Fig. 4B) through the membrane were significantly decreased in the CAL-27 and SCC-15 cell lines. These results revealed a functional role for Wnt7a in TSCC metastasis.

**Knockdown of Wnt7a suppresses EMT in TSCC cells.** Wnt7a modulates EMT and extracellular matrix degradation by targeting the canonical Wnt/β-catenin signaling in bladder cancer (25). In the present study, western blotting was performed to investigate the expression of EMT markers in Wnt7a-knockdown TSCC cell lines. Silencing Wnt7a in CAL-27 and SCC-15 cells upregulated the epithelial marker, E-cadherin, whereas the expression levels of the mesenchymal markers, N-cadherin, β-catenin and Vimentin, were inhibited, as was the EMT-associated transcriptional factor Snail (Fig. 5). These results indicated that Wnt7a may promote migration and invasion in TSCC by activating EMT activity.

**Discussion**

In most cases, diagnosis of TSCC is made when the disease has already progressed to the advanced stage. Invasion and metastasis are fundamental characteristics of advanced TSCC, and are the principal reasons behind the unfavorable outcomes for patients with TSCC. Numerous studies have suggested that Wnt signaling is associated with the metastasis and progression of TSCC (26-30); however, to the best of our knowledge, the specific ligand partners associated with Wnt signaling in this disease have not been identified. The present study revealed that Wnt7a was upregulated in TSCC tissues compared with the corresponding adjacent non-cancerous tissues from two patient cohorts. Wnt7a expression was also revealed to be closely associated with tumor growth, lymph node metastasis and tumor staging. These results were concordant with those of a previous study that conducted gene expression profiling on advanced TSCC tissues, further supporting the idea that Wnt7a is frequently overexpressed in TSCC in the favorable prognostic predicted group (31). However, an opposite result was revealed in the present survival analysis; elevated Wnt7a...
Figure 4. Effects of Wnt7a on the migration and invasion of CAL-27 and SCC-15 cells. (A) Transient knockdown of Wnt7a significantly inhibited the migratory ability of CAL-27 and SCC-15 cells, as determined by Transwell assays (one-way ANOVA and LSD test). (B) Transient knockdown of Wnt7a significantly inhibited the invasive ability of CAL-27 and SCC-15 cells, as determined by Transwell assays (one-way ANOVA and LSD test). ***P<0.001. Magnification, x200, scale bars=50 µm. ANOVA, analysis of variance; LSD, least significant difference; NC, negative control; Si, small interfering RNA.

Figure 5. Effects of Wnt7a on EMT in CAL-27 and SCC-15 cells. Knockdown of Wnt7a upregulated the expression of the epithelial marker, E-cadherin, inhibited the mesenchymal markers, N-cadherin, β-catenin and Vimentin, as well as the EMT-associated transcriptional factor Snail, in CAL-27 and SCC-15 cells. EMT, epithelial-mesenchymal transition; NC, negative control; Si, small interfering RNA.
expression was detected in patients with TSCC and an unfavorable prognosis. The results of the \textit{in vitro} study revealed the pathological and tumorigenic roles of Wnt7a in regulating invasion and metastasis of TSCC. Knockdown of Wnt7a suppressed proliferation, migration and invasion, and reversed the EMT phenotype in TSCC cells. Therefore, the present study suggested that Wnt7a may act as an oncogene in TSCC and should be considered a candidate prognostic marker for patients with TSCC.

Local lymph node and distant organ metastases are believed to be critical features of TSCC, which contribute to poor prognosis and patient mortality. Several biological behaviors are involved in this process, including EMT (32-35). EMT is an event whereby cancer cells lose their epithelial characteristics to acquire a mesenchymal phenotype, thereby enhancing their ability to migrate and invade, which is closely associated with cancer metastasis. Furthermore, EMT in cancer is associated with abnormal activation of several signaling pathways, including TGF-\(\beta\), Wnt, epidermal growth factor and fibroblast growth factor (34,36). Wnt/\(\beta\)-catenin signaling has a major impact on EMT; however, the specific Wnt ligand and the underlying downstream mechanisms are not completely understood (37,38).

The present study aimed to elucidate the role of Wnt7a in TSCC progression and EMT based on several reasons. Overexpression of Wnt7a has been reported in numerous malignant tumors, including endometrial cancer (39,40), ovarian cancer (18,41,23), colorectal cancer and pancreatic cancer (20); however, to the best of our knowledge, its role in oral cancer has not been examined. Wnt7a is mainly expressed in epithelial cells and has the capacity to control cell growth and maintain regular functioning of female reproductive organs (42-44). A previous study revealed that overexpression of Wnt7a in an ovarian cancer cell line results in the enhancement of its migratory and invasive capacities (45). In addition, it has been reported that Wnt7a, interacting with the Wnt/\(\beta\)-catenin pathway, accelerates the growth and progression of ovarian cancer (18). Therefore, it may be hypothesized that Wnt7a is mechanically involved in the reprogramming of EMT.

Using RNA interference-mediated depletion of Wnt7a to investigate the biological function of Wnt7a in TSCC, it was revealed that Wnt7a was required for the proliferation, migration and invasion of CAL-27 and SCC-15 TSCC cells. Subsequently, Wnt7a knockdown in TSCC cells was demonstrated to lead to an acquisition of an epithelial phenotype, by enhancing the expression of E-cadherin, and a loss of the mesenchymal phenotype, by suppressing the expression of N-cadherin, Vimentin and the EMT-associated transcription factor, Snail. In addition, silencing Wnt7a suppressed the expression of \(\beta\)-catenin, thus indicating that Wnt7a regulated EMT by partially antagonizing the canonical Wnt/\(\beta\)-catenin pathway. Therefore, it may be hypothesized that Wnt7a expression contributes to cancer aggressiveness by enhancing cell proliferation and metastasis, and accelerating the EMT process of TSCC.

In conclusion, the present results indicated that elevated expression of Wnt7a frequently occurred in TSCC tissues, and could be used to characterize tumor progression and predict its earlier recurrence. The present study confirmed that Wnt7a was involved in regulating cell proliferation, migration and invasion of TSCC cells, and established an important functional role for Wnt7a in TSCC pathogenesis, as revealed by its engagement in the EMT machinery.

However, the present study has several limitations. Firstly, the conclusions were based on the examination of two cell lines in which Wnt7a was silenced, and may not reflect the oncogenic role of Wnt7a in TSCC. A rescue experiment needs to be performed in the future to confirm that the re-expression of Wnt7a can restore tumor growth and metastasis of TSCC cells. Second, since this study was conducted under a retrospective design, further prospective studies with eligibility criteria applicable to clinical trials are required to confirm the findings that Wnt7a could accurately predict outcomes for patients with TSCC.

Acknowledgements

Not applicable.

Funding

The present study was financially supported by the Science and Technology Project of Guangzhou Province (201802020018) and the Medical Science and Technology Research Project of Guangdong (B2017103).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

XQ and JZ were involved in the experimental conception and design. XQ and BJ performed the experiments. HC conducted the data analysis. XS contributed to the reagents, materials and tools. SX and XZ contributed to the conception of the study and wrote the manuscript. All authors read and approved the final manuscript. All authors contributed toward data analysis, drafting and critically revising the paper, and agree to be accountable for all aspects of the work.

Ethics approval and consent to participate

All patients provided informed consent for the use of their tissues and clinical data. The present study was approved by the Independent Ethics Committee of the Stomatological Hospital, Southern Medical University (approval no.[2018]05). The animal study was conducted in accordance with the Institutional Animal Care and Use Committee guidelines, and was approved by the Experimental Animal Ethics Committee of Southern Medical University (approval no. L2016113).

Patient consent for publication

All patients recruited provided consent for publication.

Competing interests

The authors declare that they have no competing interests.
References